Literature DB >> 9325244

Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.

M E Quiñones-Mateu1, V Soriano, E Domingo, L Menéndez-Arias.   

Abstract

The catalytic properties and sensitivity to different inhibitors have been determined for the reverse transcriptase (RT) of group O human immunodeficiency virus type 1 (HIV-1). The RT-coding region was cloned from a new HIV-1 group O isolate from Spain, expressed in Escherichia coli, and purified by affinity chromatography. This new RT showed 79% amino acid sequence identity with the corresponding enzyme of group M subtype B strain BH10. The two enzymes showed very similar kinetics of RNA-dependent DNA polymerization using homopolymeric template-primers and RNase H specific activity. Inhibitor sensitivity to ddTTP and 3'-azido-2',3'-dideoxythymidine triphosphate (AZTTP) was also similar for both enzymes. However, the two enzymes differed dramatically in their sensitivity to several inhibitors. While the RT of the BH10 isolate was sensitive to nevirapine and loviride (IC50 ranged from 0.16 to 8.2 microM, depending on the substrates used), the enzyme of the Spanish HIV-1 group O isolate showed high-level resistance to those compounds (IC50 > 200 microM). The amino acid sequence of the RT of group O HIV-1 contains three amino acids (Cys-181, Glu-179, and Gly-98), which are found in group M subtype B strains resistant to nonnucleoside RT inhibitors. The recombinant group O HIV-1 RT should be useful for studies aimed at discovering and designing drugs directed toward group O isolates of HIV-1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325244     DOI: 10.1006/viro.1997.8748

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.

Authors:  J G García Lerma; V Soriano; A Mas; M E Quiñones-Mateu; E J Arts; W Heneine
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

3.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

4.  Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands.

Authors:  L Medrano; L Menéndez-Arias; R De Jorge; M L Villahermosa; G Contreras; L Pérez-Alvarez; A Moya; R Nájera
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

5.  Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.

Authors:  Berta Rodés; Eva Poveda; Vincent Soriano
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Novel Time-Resolved Fluorescence Europium Nanoparticle Immunoassay for Detection of Human Immunodeficiency Virus-1 Group O Viruses Using Microplate and Microchip Platforms.

Authors:  Mohan Kumar Haleyur Giri Setty; Jikun Liu; Prerna Mahtani; Panhe Zhang; Bingchen Du; Viswanath Ragupathy; Krishnakumar Devadas; Indira K Hewlett
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-15       Impact factor: 2.205

7.  Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.

Authors:  M Mracna; G Becker-Pergola; J Dileanis; L A Guay; S Cunningham; J B Jackson; S H Eshleman
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

8.  Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.

Authors:  Oyebisi Jegede; Ana Khodyakova; Mikhail Chernov; Jan Weber; Luis Menéndez-Arias; Andrei Gudkov; Miguel E Quiñones-Mateu
Journal:  Antiviral Res       Date:  2011-05-12       Impact factor: 5.970

9.  Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity.

Authors:  Kalonji R Collins; Miguel E Quiñones-Mateu; Mianda Wu; Henry Luzze; John L Johnson; Christina Hirsch; Zahra Toossi; Eric J Arts
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

10.  Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.

Authors:  M E Quiñones-Mateu; J L Albright; A Mas; V Soriano; E J Arts
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.